Core Viewpoint - Puli Pharmaceutical (300630) is facing potential delisting due to significant violations related to false disclosures in its 2021 and 2022 annual reports, as identified by the China Securities Regulatory Commission (CSRC) [1][2][3] Group 1: Regulatory Actions - On January 5, Puli Pharmaceutical announced it received an administrative penalty notice from the CSRC, indicating that its 2021 and 2022 annual reports contained false records [1] - The company is set to be placed under a major violation delisting risk warning starting January 7, pending the final administrative penalty decision [1][3] - The CSRC has initiated an investigation into the company for suspected information disclosure violations [2] Group 2: Financial Misrepresentation - The CSRC's notice revealed that the total false revenue reported for 2021 and 2022 amounted to approximately 1.031 billion yuan, representing 31.08% of the total reported revenue for those years [2] - The total false profit reported for the same period was approximately 695 million yuan, accounting for 76.72% of the total reported profit [2][3] Group 3: Consequences and Market Reactions - Puli Pharmaceutical's stock will be suspended for one day on January 6 and will receive a delisting risk warning starting January 7 [3] - The company must disclose updates on the situation every five trading days during the delisting risk warning period [3] - The company has faced over 30 risk warning announcements regarding the potential for major violations leading to delisting [5] Group 4: Broader Regulatory Context - The Chinese government has adopted a "zero tolerance" policy towards financial fraud, emphasizing strict enforcement of delisting regulations [7] - Recent regulatory measures aim to enhance accountability for financial misconduct, including potential criminal charges for responsible parties [7][8] - The ongoing crackdown on financial fraud is intended to restore investor confidence and maintain market integrity [8]

Revenue and Profitability - For the six months ended 30 June 2024, the Group's revenue decreased by HK$1.3 million or 5.6% to HK$22.0 million compared to HK$23.3 million in the same period last year[4] - Gross profit increased by HK$1.9 million or 38.8% to HK$6.8 million, with a gross profit margin rising by 9.7 percentage points to 30.8%[4] - The Medical Products Business generated revenue of HK$16.3 million, accounting for 74.2% of the Group's total revenue, remaining stable compared to HK$16.4 million in the previous year[6] - The Money Lending Business recorded loan interest income of HK$5.7 million, a decrease of HK$0.3 million or 5.0% from HK$6.0 million in the prior year, representing 25.8% of total revenue[14] - The overall loss attributable to owners of the Company was HK$25.4 million, a decrease of HK$4.3 million compared to a loss of HK$29.7 million in the corresponding period of 2023[5] - The segment profit of the Medical Products Business increased to HK$1.7 million from HK$1.4 million in the previous year, indicating effective cost management strategies[9] - The Group's lending business segment reported a loss of HK$700,000 for the period, an improvement from a loss of HK$800,000 in the same period last year[15] - The loss before income tax improved to HK$25,429,000, a reduction of 14.8% from HK$29,673,000 in the previous year[51] Expenses and Cost Management - Distribution costs decreased by HK$0.5 million to HK$2.2 million, while administrative expenses decreased by HK$4.2 million or 41.6% to HK$5.9 million due to stringent cost control[5] - Other losses during the period amounted to HK$22.9 million, compared to a loss of HK$20.3 million in the same period last year, influenced by fair value changes in securities investments[4] - The Group's securities investment segment incurred a net unrealised and realised loss of HK$22.9 million for the six months ended June 30, 2024, compared to a loss of HK$11.0 million for the same period last year[15] Financial Position - As of June 30, 2024, the Group's consolidated net asset was approximately HK$35.9 million, a decrease of approximately HK$25.5 million from HK$61.4 million as of December 31, 2023[23] - The Group's total cash and bank balances amounted to approximately HK$4.6 million as of June 30, 2024, down HK$3.1 million from HK$7.7 million as of December 31, 2023[23] - The Group's gearing ratio increased to 73.2% as of June 30, 2024, compared to 37.8% as of December 31, 2023[23] - The Group's current ratio was 2.0 as of June 30, 2024, down from 2.2 as of December 31, 2023[24] - The Group had no borrowings from financial institutions as of June 30, 2024, and December 31, 2023[23] - The Group had bond payables of HK$30.0 million as of June 30, 2024, unchanged from December 31, 2023[23] - The Group's total trade and other receivables as of June 30, 2024, amounted to HK$94,586,000, down from HK$108,272,000 as of December 31, 2023, indicating a reduction of about 12.6%[84] - Trade receivables from contracts with customers were HK$41,798,000 as of June 30, 2024, compared to HK$45,294,000 as of December 31, 2023, reflecting a decrease of approximately 7.3%[84] Investment Strategy - The Group aims to enhance competitiveness by revitalizing its scaffolding business and focusing on segments with higher profit margins, such as money lending operations[18] - The Group will continue to maintain a diversified investment portfolio to minimize potential financial risks and will conduct constant performance appraisals to evaluate ongoing business development[20] - The Group's investment strategy focuses on maximizing sustained long-term returns while maintaining stable growth in traditional business areas[19] - As of June 30, 2024, the Group held 27 listed equity securities in Hong Kong with a fair value of HK$25.3 million, and intends to diversify its investment portfolio to reduce concentration and investment risks[15] Share Options and Corporate Governance - The company has granted share options totaling 3,724,000 shares to each of the three directors, representing approximately 0.38% of the issued share capital as of June 30, 2024[33] - The share options were granted under the Share Option Scheme at an exercise price of HK$0.435 per share, established on May 4, 2020[34] - The maximum number of shares that may be issued upon the exercise of all share options under the Share Option Scheme is capped at 10% of the issued share capital on the date of approval[39] - The Share Option Scheme is valid for ten years and will expire on June 29, 2025[39] - The company has complied with all provisions of the Corporate Governance Code for the six months ended June 30, 2024[50] - The audit committee consists of three independent non-executive directors who reviewed the accounting principles and practices adopted by the group[50] Employee and Management Information - The Group's employee count remained stable at 30 as of June 30, 2024, consistent with December 31, 2023[29] - The remuneration for key management personnel decreased slightly from HK$426,000 in the previous year to HK$408,000 for the six months ended June 30, 2024[98] Other Financial Information - The Group incurred no depreciation charge on property, plant, and equipment for the six months ended June 30, 2024, compared to HK$140,000 for the same period in 2023[81] - The Group allows a credit period of up to 90 days to its trade customers, consistent with the previous period[85] - The Group's loan receivables are interest-bearing at rates ranging from 4% to 12% per annum, consistent with the previous period[86] - The total trade and other payables decreased from HK$76,457,000 as of December 31, 2023, to HK$66,698,000 as of June 30, 2024, a decrease of approximately 12.7%[88]

Financial Performance - For the six months ended June 30, 2024, the Group's revenue amounted to HK$22.0 million, a decrease of HK$1.3 million or 5.6% from HK$23.3 million in the corresponding period last year[7]. - The Group's gross profit was HK$6.8 million, representing an increase of HK$1.9 million or 38.8% compared to HK$4.9 million for the same period last year, with a gross profit margin increase of 9.7 percentage points to 30.8%[7]. - The overall loss attributable to owners of the Company was HK$25.4 million, a decrease of HK$4.3 million compared to a loss of HK$29.7 million for the same period last year[9]. - Revenue for the six months ended June 30, 2024, was HK$22,007,000, a decrease of 5.4% compared to HK$23,259,000 in 2023[54]. - Gross profit increased to HK$6,782,000, up 38.1% from HK$4,906,000 in the previous year[54]. - Loss before income tax improved to HK$25,429,000, a reduction of 14.8% from HK$29,673,000 in 2023[54]. - Basic and diluted loss per share improved to HK(2.63) cents from HK(3.36) cents in the previous year[54]. - The consolidated loss before income tax for the six months ended June 30, 2024, was HK$25,429,000, compared to a loss of HK$29,673,000 for the same period in 2023, indicating an improvement of approximately 14.8%[77]. Revenue Breakdown - Revenue from the Medical Products Business was stable at HK$16.3 million, compared to HK$16.4 million in the same period last year, accounting for 74.2% of the Group's total revenue[9]. - Revenue from the Plastic Products Business decreased to HK$Nil million, down from HK$0.6 million in the same period last year, accounting for 0% of the Group's total revenue[12]. - Revenue from external customers for the Medical Devices Business was HK$16,327,000 for the six months ended 30 June 2024[67]. - The Money Lending Business generated revenue of HK$5,680,000 during the same period[67]. - Total reportable segment revenue for the Group was HK$22,007,000 for the six months ended 30 June 2024[67]. Expenses and Costs - Other losses during the period amounted to HK$22.9 million, compared to a loss of HK$20.3 million in the corresponding period of 2023[7]. - Distribution costs decreased by HK$0.5 million to HK$2.2 million during the period under review[9]. - Administrative expenses decreased by HK$4.2 million to HK$5.9 million, representing a decrease of 41.6% over the corresponding period last year[9]. - Finance costs amounted to HK$1.2 million, down from HK$1.4 million in the same period last year[9]. - The cost of inventories recognized as expenses for the six months ended June 30, 2024, was HK$15,225,000, a decrease from HK$17,908,000 in 2023, indicating a reduction of approximately 15%[83]. Investment and Assets - The Group recorded a net unrealised and realised loss of HK$22.9 million from its securities investment, compared to a loss of HK$11.0 million for the same period last year[19]. - As of 30 June 2024, the outstanding principal and interest amount of loan receivables was HK$147.0 million, down from HK$153.5 million as of 31 December 2023[16]. - As of June 30, 2024, the Group's consolidated net asset was approximately HK$35.9 million, a decrease of approximately HK$25.5 million from HK$61.4 million as of December 31, 2023[30]. - The Group's total cash and bank balances amounted to approximately HK$4.6 million as of June 30, 2024, down HK$3.1 million from HK$7.7 million as of December 31, 2023[30]. - The Group's gearing ratio increased to 73.2% as of June 30, 2024, compared to 37.8% as of December 31, 2023[30]. Share Options and Capital - The Share Option Scheme was adopted on June 30, 2015, to incentivize eligible participants for their contributions to the Group[45]. - The maximum number of shares that may be issued upon the exercise of all share options under the Share Option Scheme is capped at 10% of the issued share capital of the Company at the time of approval[46]. - The exercise price of share options must be at least the highest of the closing price on the grant date, the average closing price for the five business days preceding the grant date, or the nominal value of a share[46]. - The Company has authorized a maximum of 48,377,589 share options under the Share Option Scheme as of June 30, 2022[48]. - The issued and fully paid share capital as of June 30, 2024, is 967,551,792 shares, totaling HK$48,378,000[106]. Corporate Governance - The Company has complied with all code provisions of the Corporate Governance Code for the six months ended June 30, 2024[53]. - The Audit Committee has reviewed the accounting principles and practices adopted by the Group and discussed financial reporting matters for the six months ended June 30, 2024[53]. - The Company has confirmed full compliance with the Model Code for securities transactions by Directors during the six months ended June 30, 2024[53]. Employee and Management - The Group has 30 employees as of June 30, 2024, with remuneration largely based on performance and industry practices[39]. - The remuneration of key management personnel for the six months ended June 30, 2024, was HK$408,000, a decrease from HK$426,000 in the same period of 2023[109].

Financial Performance - The total revenue of AMCO United Holding Limited decreased by HK$32.2 million or 48.4%, from HK$66.5 million in 2022 to HK$34.3 million in 2023[13]. - The loss for the year improved significantly to HK$2.75 million in 2023 from HK$104.25 million in 2022[6]. - Overall loss attributable to owners of the Company was HK$2.8 million, a significant decrease of 97.3% from a loss of HK$104.3 million in 2022[31]. - The Group recorded a realized and unrealized loss of HK$8.5 million in 2023 from changes in the fair value of held-for-trading investments, compared to a loss of HK$4.6 million in 2022[153]. - The segment loss from Securities Investment amounted to HK$8.8 million in 2023, an increase from a loss of HK$4.6 million in 2022[153]. Equity and Assets - Equity attributable to owners of the Company increased to HK$61.36 million in 2023 from HK$18.59 million in 2022[6]. - The Group's consolidated net assets increased to HK$61.4 million as of December 31, 2023, up from HK$18.6 million as of December 31, 2022[165]. - The Group's total cash and bank balances amounted to HK$7.7 million as of December 31, 2023, an increase of HK$4.0 million from HK$3.7 million as of December 31, 2022[169]. - As of December 31, 2023, the carrying amount of the plant and machinery is approximately HK$Nil, down from HK$1.1 million in 2022[98]. Financial Ratios - The current ratio improved to 2.2 in 2023 from 1.7 in 2022, indicating better short-term financial health[6]. - The total debt to total assets ratio decreased to 0.6 in 2023 from 0.9 in 2022, reflecting reduced leverage[6]. - The Group's gearing ratio improved to 37.8% as of December 31, 2023, compared to 277.1% as of December 31, 2022[174]. Revenue Breakdown - Revenue from medical products dropped by 59.7% or HK$32.5 million, accounting for 63.9% of the Group's total revenue in 2023[37]. - Revenue from the Building Contract Works Business decreased due to fewer contract awards in both public and private sectors[17]. - Revenue from the Medical Products Business totaled HK$21.9 million for the year ended December 31, 2023, with Customer A contributing HK$10.1 million and Customer B contributing HK$8.3 million[112]. - Revenue from Plastic Products decreased by 45.5% to HK$0.6 million, accounting for 1.8% of the Group's total revenue, with a segment loss of approximately HK$829,000[118][123]. Business Segments - The Money Lending Business generated stable income for the Group in 2023, contrasting with losses in the Securities Investment segment[18]. - The Building Contract Works Business generated no revenue for the year, a decrease of HK$2.7 million or 100%, resulting in a segment loss of HK$1.0 million[120][124]. - Loan interest income from Money Lending increased by 8.3% to HK$11.8 million, accounting for 34.3% of the Group's total revenue, with a segment profit of HK$14.7 million[127]. Cost Management - Distribution and administrative expenses decreased by HK$11.0 million or 44.0% to HK$14.0 million compared to HK$25.0 million in 2022[30]. - The Group is implementing strict cost control measures and streamlining business processes to maintain competitive advantages[14]. Credit and Risk Management - The expected credit loss (ECL) provision was reversed by approximately HK$7.9 million in 2023, compared to a provision of approximately HK$76.3 million in 2022[31]. - The credit loss rate applied for loan receivables was 47.1% in 2023, slightly up from 46.3% in 2022[36]. - JS Finance has adjusted its lending strategy to enhance borrower requirements, including the need for asset or income proof to lower the default ratio[132]. Investment Strategy - The Group intends to diversify its investment portfolio to reduce concentration and investment risks due to recent market volatility[154]. - The Group will maintain a prudent investment attitude and develop strategies to improve capital usage efficiency and generate additional returns on idle funds[154]. Operational Efficiency - The Group will focus on reallocating assets and resources to adapt to changing market conditions and enhance operational efficiency[23]. - The Group emphasizes just-in-time production to minimize storage costs and the risk of obsolete stock, adjusting production volumes and pricing strategies based on actual market demand[92]. Employee Management - As of December 31, 2023, the group has 30 employees, maintaining the same number as the previous year[183]. - Employee compensation is determined based on performance and experience, with benefits including salary, insurance, mandatory provident fund, and stock option plans[183]. Corporate Governance - The company has complied with all code provisions of the Corporate Governance Code throughout the year ended December 31, 2023, with certain disclosed deviations[200].

Financial Performance - For the year ended December 31, 2023, the total revenue was HKD 34,333,000, a decrease of 48.3% compared to HKD 66,489,000 in 2022[4] - The gross profit for the same period was HKD 14,808,000, slightly up from HKD 14,688,000 in 2022, indicating a stable gross margin despite lower revenue[4] - The net loss attributable to the company's owners was HKD 2,753,000, significantly improved from a loss of HKD 104,251,000 in the previous year, representing a reduction of 97.4%[5] - Revenue from continuing operations decreased to HKD 34,333 thousand in 2023 from HKD 66,489 thousand in 2022, representing a decline of 48.3%[25] - The reported segment performance improved to a profit of HKD 8,382 thousand in 2023 compared to a loss of HKD 70,125 thousand in 2022[25] - The company reported a loss before tax from continuing operations of HKD 1,713 thousand in 2023, significantly improved from a loss of HKD 104,293 thousand in 2022[25] - The company reported a significant reduction in total liabilities from HKD 151,765 thousand in 2022 to HKD 105,753 thousand in 2023, a decrease of 30.4%[25] - The group recorded realized and unrealized losses of approximately HKD 8,500,000 from trading investments in listed securities for the year ending December 31, 2023, compared to a loss of HKD 4,600,000 in 2022[93] Assets and Equity - The total assets as of December 31, 2023, were HKD 168,718,000, compared to HKD 166,494,000 in 2022, showing a slight increase of 1.3%[7] - The company's cash and cash equivalents increased to HKD 7,716,000 from HKD 3,722,000, reflecting a growth of 107.1% year-over-year[7] - The total equity rose to HKD 61,361,000, a significant increase from HKD 18,589,000 in 2022, marking a growth of 230.5%[7] - As of December 31, 2023, the group's net asset value increased to HKD 61,400,000 from HKD 18,600,000 as of December 31, 2022, representing an increase of HKD 42,800,000[98] Business Operations - The company has terminated its construction services business, focusing on medical product sales and plastic mold sales moving forward[8] - The company plans to closely monitor loan collections and implement strict cost control measures to optimize operational efficiency[11] - The company continues to evaluate its business segments independently due to the different products and services offered, which require distinct business strategies[18] - The company plans to focus on developing high-quality medical products and expanding its service team to enhance competitiveness in the medical products market[79] Segment Performance - Total revenue from external customers for the year ended December 31, 2023, was HKD 34,333,000, with contributions from medical products (HKD 21,938,000), plastic products (HKD 635,000), and lending (HKD 11,760,000) [21] - The reported segment performance showed a profit of HKD 3,262,000 from medical products, while the plastic products segment incurred a loss of HKD 829,000, and the lending segment generated a profit of HKD 14,744,000 [21] - Revenue from medical products sales was HKD 21,938 thousand in 2023, down from HKD 54,422 thousand in 2022, a decrease of 59.7%[32] - The medical products segment achieved a profit of HKD 3,300,000 for the year ended December 31, 2023, compared to a loss of HKD 25,600,000 in the previous year, primarily due to the recognition of expected credit loss provisions in the prior year[50] Credit and Lending - The expected credit loss for lending was approximately HKD 5,500,000, significantly reduced from HKD 47,400,000 in the previous year, indicating improved credit management[85] - The company received 71 loan renewal applications, all of which were successfully approved, with loan amounts ranging from HKD 100,000 to HKD 10,000,000[86] - The largest receivable from a single borrower was approximately HKD 4,100,000, accounting for 5.0% of total receivables[86] Investment Strategy - The group plans to diversify its investment portfolio to reduce concentration and investment risks amid recent market volatility[93] - The group is committed to maintaining a diversified investment strategy to minimize potential financial risks while ensuring stable growth in traditional business[96] - The group will closely monitor the performance of its investment portfolio and make necessary adjustments based on market dynamics[96] Corporate Governance - The company has adhered to the corporate governance code as per the Hong Kong Stock Exchange rules throughout the fiscal year ending December 31, 2023[111] - The audit committee consists of three independent non-executive directors, ensuring compliance with accounting principles and internal controls[115] - The financial figures in the preliminary announcement are consistent with the draft annual consolidated financial statements, as verified by the auditor Privatco CPA Limited[116] Employee and Operational Management - The management team has extensive experience in the medical products industry, with some members having over 10 years of experience, which is crucial for the group's future growth[56] - The company provides training for both new and existing employees to ensure skilled labor in production processes[71] - The company collaborates closely with the sales team to ensure customer requirements are met effectively during product development[67]

Financial Performance - For the six months ended June 30, 2023, the Group's revenue was HK$23.3 million, a decrease of HK$1.7 million or 6.8% from HK$25.0 million in the same period last year[6]. - Gross profit for the Group was HK$4.9 million, down HK$2.2 million or 31.0% compared to HK$7.1 million for the same period last year, with a gross profit margin of 21.1%, a decrease of 7.2 percentage points from 28.3%[7]. - The overall loss attributable to owners of the Company was HK$29.7 million, a slight decrease of HK$0.5 million from a loss of HK$30.2 million in the corresponding period of 2022[14]. - Revenue for the six months ended June 30, 2023, was HK$23,259,000, a decrease of 7.0% from HK$25,030,000 in the same period of 2022[116]. - Gross profit for the period was HK$4,906,000, down 30.7% from HK$7,071,000 year-on-year[116]. - Loss before income tax for the period was HK$29,673,000, slightly improved from a loss of HK$30,201,000 in the previous year[116]. - The Group reported a total segment loss of HK$10,445,000 for the six months ended June 30, 2023, compared to a loss of HK$11,390,000 for the same period in 2022, indicating an improvement in performance[144][150]. Revenue Breakdown - Revenue from the Medical Products Business decreased by HK$0.6 million or 3.5% to HK$16.4 million, accounting for 70.4% of the Group's total revenue[15]. - Revenue from the Plastic Products Business decreased by HK$0.6 million or 50.0% to HK$0.6 million, representing 2.7% of the Group's total revenue[21]. - Revenue from the Building Contract Works Business decreased by HK$1.0 million or 76.9% to HK$0.3 million for the six months ended 30 June 2023, contributing 1.1% of the Group's total revenue[25]. - The Medical Devices Business generated revenue of HK$16,380,000, while the Plastic Moulding Business contributed HK$635,000, and the Building Contract Works Business brought in HK$250,000 for the first half of 2023[144]. Expenses and Costs - Administrative expenses decreased by HK$11.6 million to HK$10.1 million, a reduction of 53.5% compared to HK$21.7 million in the same period last year[12]. - Finance costs for the period were HK$1.4 million, down from HK$1.8 million in the same period last year[13]. - Staff costs, including directors' emoluments, amounted to HK$1,738,000 for the first half of 2023, significantly lower than HK$10,877,000 in the same period of 2022, indicating a reduction of 84.0%[166]. Investment and Financial Position - The Group's total investment in WLS was approximately HK$45.5 million, representing 1.4% equity interests in WLS[40]. - The carrying amount of the Group's interest in WLS was approximately HK$11.1 million, accounting for about 6.9% of the total assets of the Company[40]. - The outstanding principal and interest amount of loan receivables as of 30 June 2023 was HK$94.3 million, up from HK$90.1 million as of 31 December 2022[30]. - The Group's total cash and bank balances increased to approximately HK$10.8 million as of June 30, 2023, compared to HK$3.7 million as of December 31, 2022[58]. - The Group's consolidated net assets increased to approximately HK$36.5 million, up from HK$18.6 million as of December 31, 2022[49]. Share Capital and Rights Issue - The Group completed a rights issue on February 1, 2023, issuing 483,775,896 rights shares, with estimated net proceeds of approximately HK$46.5 million[51]. - Approximately 71.4% or HK$33.2 million of the net proceeds from the rights issue is intended for repayment of bond payables[53]. - The total authorized share capital as of June 30, 2023, is 80,000,000,000 shares amounting to HK$400,000,000[200]. - The issued and fully paid shares increased from 483,775,896 shares (HK$24,189,000) on January 1, 2023, to 967,551,792 shares (HK$48,378,000) by June 30, 2023[200]. Corporate Governance and Compliance - The Company has complied with all provisions of the Corporate Governance Code for the six months ended June 30, 2023, except for the combined roles of Chairman and Managing Director held by Mr. Zhang Hengxin[106][107]. - The Audit Committee, comprising three Independent Non-executive Directors, reviewed the accounting principles and practices adopted by the Group and discussed financial reporting matters for the six months ended June 30, 2023[112]. - The Company did not purchase, sell, or redeem any of its listed securities during the six months ended June 30, 2023[113]. Future Outlook and Strategy - The Group is actively exploring potential business opportunities to expand its customer base and product portfolio in the Medical Products Business[19]. - The Group intends to diversify its investment portfolio to reduce concentration and investment risks in light of market volatility[34]. - The Group will continue to focus on projects with higher margins and manage costs effectively to improve business results[28]. - The Group aims to maintain a diversified investment portfolio to minimize financial risks amid economic uncertainties[44]. - The Group will focus on optimizing its business portfolio and exploring new growth opportunities to maximize shareholder value[46].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何 部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 （於百慕達註冊成立之有限公司） （股份代號：630） 二零二三年中期業績公告 雋泰控股有限公司（「本公司」）董事會（「董事會」）欣然宣佈本公司及其附屬公司 截至二零二三年六月三十日止六個月的未經審核綜合業績。本公告列載本公司二 零二三年中期報告的全文，並符合香港聯合交易所有限公司證券上市規則（「上市 規則」）中有關中期業績初步公告附載的資料要求。 為及代表董事會 雋泰控股有限公司 主席兼董事總經理 張亨鑫 香港，二零二三年八月二十八日 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何 部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 （於百慕達註冊成立之有限公司） （股份代號：630） 有關截至二零二二年報之 補充公告 茲提述雋泰控股有限公司（「本公司」）截至二零二二年十二月三十一日止年度之 年報（「二零二二年報」）。除另行界定外，本公告所用詞彙與二零二二年報內所界 定者具相同涵義。 除二零二二年報中的董事會報告當中「購股權計劃」一節及綜合財務報表附註29 所披露的內容外，本公司欲提供以下有關購股權計劃的額外資料。 截至二零二二年一月一日及二零二二年十二月三十一日，根據計劃授權授出及根 據購股權計劃可發行的購股權總數分別為48,377,589份及48,377,589份。購股權計劃 並無設定服務提供者分項限額。 ...

Financial Performance - The total revenue of AMCO United Holding Limited decreased by HK$2.7 million or 3.8%, from HK$71.9 million in 2021 to HK$69.2 million in 2022[15]. - The loss for the year increased significantly to HK$104.3 million in 2022, compared to a loss of HK$18.1 million in 2021[7]. - The equity attributable to owners of the Company dropped to HK$18.6 million in 2022 from HK$114.8 million in 2021[7]. - The total assets decreased from HK$184.8 million in 2021 to HK$172.8 million in 2022[7]. - The current ratio declined from 2.3 in 2021 to 1.7 in 2022, indicating a decrease in liquidity[7]. - The total debt to total assets ratio increased from 0.4 in 2021 to 0.9 in 2022, reflecting higher leverage[7]. - The return on total assets was recorded at (60.3%) in 2022, compared to (9.8%) in 2021, indicating a significant decline in asset efficiency[7]. - The return on sales also worsened to (150.6%) in 2022 from (25.2%) in 2021, highlighting increased operational losses relative to revenue[7]. Business Segments Performance - Revenue from Medical Products was HK$54.4 million, a decrease of 4.1% or HK$2.3 million compared to HK$56.7 million in the previous year, representing 78.6% of the Group's total revenue[38]. - The Medical Products segment recorded a loss of HK$25.6 million for the year ended December 31, 2022, compared to a profit of HK$0.5 million in 2021, primarily due to the provision for expected credit loss[42]. - Revenue from the Plastic Products segment increased by 175% or HK$0.7 million to HK$1.1 million, but accounted for only 1.6% of the Group's total revenue[44]. - Revenue from the Building Contract Works Business decreased by HK$1.4 million or 34.1% to HK$2.7 million, contributing 3.9% of the Group's total revenue[48]. - The Building Contract Works segment achieved a gain of HK$42,000 for the year ended December 31, 2022, a significant improvement from a loss of HK$7.6 million in 2021, mainly due to reduced staff costs[50]. - The Group's Money Lending Business turned from profit to loss in the current year, while the Securities Investment segment recorded a profit[22]. Credit Risk and Provisions - The expected credit loss (ECL) provision was approximately HK$74.7 million, up from HK$14.4 million in 2021, reflecting a credit loss rate of 46.3%[37]. - The expected credit loss rate for receivables as of December 31, 2022, was 46.3%, up from 23.3% in 2021, reflecting increased credit risk amid the COVID-19 pandemic[39]. - The Group recognized net impairment losses of approximately HK$47.4 million due to expected credit losses, compared to approximately HK$9.1 million in 2021, indicating a significant increase in credit risk[58]. - To mitigate default risk, the Group has enhanced loan requirements, including the necessity for borrowers to provide asset or income proof[57]. Investment Strategy - The Group intends to adopt a prudent investment attitude and develop its investment strategy to improve capital usage efficiency and generate additional returns on idle funds[77]. - The Group plans to closely monitor the performance of its investment business in light of recent market volatility, aiming to reduce concentration and investment risks[77]. - The Group maintained a diversified investment portfolio to minimize financial risks and will assess the performance of investments regularly[86]. - The Group's investment strategy aims for sustained long-term returns while traditional business continues stable growth[87]. Corporate Governance - The Company has complied with all code provisions of the Corporate Governance Code throughout the year ended 31 December 2022[121]. - All Directors have confirmed full compliance with the Model Code for Securities Transactions during the year ended 31 December 2022[122]. - The Board consists of two Executive Directors and three Independent Non-executive Directors, ensuring a balanced governance structure[124]. - The Company has a commitment to maintaining high standards of corporate governance and shareholder accountability[121]. - The company has arranged liability insurance for directors and officers to cover costs incurred in the execution of their duties[156]. Board Composition and Meetings - The Board of Directors held two meetings during the year, with all members attending 100% of the meetings[129]. - The Nomination Committee is responsible for reviewing the structure, size, and diversity of the Board at least annually[170]. - The Nomination Committee evaluated candidates based on character, qualifications, skills, and diversity in line with the company's corporate strategy[175]. - The Audit Committee also conducted two meetings, with full attendance from its members[184]. - The Remuneration Committee held two meetings during the year, with all members attending[166]. Financial Management - The Group's total cash and bank balances amounted to HK$3.7 million as of December 31, 2022, a decrease of HK$1.0 million from HK$4.7 million as of December 31, 2021[92]. - The Group's gearing ratio increased to 277.1% as of December 31, 2022, compared to 25.8% as of December 31, 2021[93]. - The Directors prepared the financial statements for the year ended December 31, 2022, on a going concern basis[200].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任 何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 （於百慕達註冊成立之有限公司） （股份代號：630） 截至二零二二年十二月三十一日止年度之業績公告 業績 雋泰控股有限公司（「本公司」）董事（「董事」）會（「董事會」）宣佈，本公司及其附 屬公司（以下統稱為「本集團」）截至二零二二年十二月三十一日止年度經審核綜 合業績連同去年之比較數字如下。 綜合損益及其他全面收益表 截至二零二二年十二月三十一日止年度 二零二二年 二零二一年 附註 千港元 千港元 收入 5 67,159 71,891 銷售及服務成本 (52,442) (57,776) 毛利 14,717 14,115 其他收入及其他收益或虧損 6 (16,341) 680 分銷成本 (1,626) (718) 行政開支 (27,223) (14,789) ...